Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
MIGDAL HA'EMEQ, Israel, May 03, 2017 -- Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec" or the "Company"), a developer, manufacturer and marketer of innovative bio-active lipid-based nutritional ingredients and medical foods, announced today that the Company will release financial results for the first quarter ended March 31, 2017 on Wednesday, May 17, 2017, before the market opens. Following the release, Erez Israeli, President and Chief Executive Officer, and Oren Bryan, Vice President and Chief Financial Officer, will host a conference call to review the financial results.
The conference call is scheduled to begin at 8:30 am ET on Wednesday, May 17, 2017. Participants should dial +1 877-359-9508 (United States) or +1 224-357-2393 (International) with confirmation code #17202050 to access the live call. The call will also be broadcast live over the Internet, hosted in the Investors section of Enzymotec's website at http://edge.media-server.com/m/p/qhzwbm72, and will be archived online within one hour of its completion.
About Enzymotec Ltd.
Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-active lipid ingredients, as well as final products, based on sophisticated processes and technologies. For more information, visit http://www.enzymotec.com.
Contact: The Ruth Group Tram Bui / Alexander Lobo (646) 536-7035 / 7037 [email protected] [email protected]
